ASP Isotopes Inc. (NASDAQ:ASPI – Get Free Report) Director Robert John Andrew Ryan purchased 4,313 shares of the stock in a transaction that occurred on Monday, April 29th. The shares were bought at an average cost of $3.20 per share, for a total transaction of $13,801.60. Following the acquisition, the director now owns 555,868 shares of the company’s stock, valued at $1,778,777.60. The transaction was disclosed in a filing with the SEC, which is available through this link.
Robert John Andrew Ryan also recently made the following trade(s):
- On Thursday, April 25th, Robert John Andrew Ryan acquired 9,500 shares of ASP Isotopes stock. The shares were bought at an average cost of $3.42 per share, with a total value of $32,490.00.
ASP Isotopes Stock Performance
Shares of NASDAQ ASPI traded down $0.03 during trading on Wednesday, hitting $3.14. 142,881 shares of the company were exchanged, compared to its average volume of 581,597. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.85 and a quick ratio of 1.85. ASP Isotopes Inc. has a 1 year low of $0.28 and a 1 year high of $4.97. The firm’s fifty day moving average price is $3.72 and its 200 day moving average price is $2.53.
Analyst Ratings Changes
Separately, HC Wainwright lifted their target price on ASP Isotopes from $5.25 to $5.50 and gave the company a “buy” rating in a research note on Wednesday, April 17th.
View Our Latest Stock Report on ASPI
Institutional Inflows and Outflows
An institutional investor recently bought a new position in ASP Isotopes stock. HTLF Bank bought a new stake in ASP Isotopes Inc. (NASDAQ:ASPI – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 78,538 shares of the company’s stock, valued at approximately $141,000. HTLF Bank owned approximately 0.16% of ASP Isotopes as of its most recent filing with the Securities and Exchange Commission. 16.80% of the stock is currently owned by hedge funds and other institutional investors.
About ASP Isotopes
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.
Featured Articles
- Five stocks we like better than ASP Isotopes
- Want to Profit on the Downtrend? Downtrends, Explained.
- Amazon Stands Tall: New Highs Are in Sight
- Bank Stocks – Best Bank Stocks to Invest In
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
- P/E Ratio Calculation: How to Assess Stocks
- 5 Aerospace & Defense Stocks Ready for Liftoff
Receive News & Ratings for ASP Isotopes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASP Isotopes and related companies with MarketBeat.com's FREE daily email newsletter.